Your session is about to expire
← Back to Search
Other
Dasatinib + Quercetin for Bone Marrow Transplant Survivors (HTSS Trial)
N/A
Recruiting
Led By Nathan K LeBrasseur, MS, PhD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Diagnosis of both malignant and non-malignant conditions as HSCT indications
HSCT survivors receiving any type of conditioning chemo/radiotherapy for HSCT
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 180 days
Awards & highlights
HTSS Trial Summary
This trial will help the investigators understand if their concept is correct, so that they can design a bigger study based on the results.
Who is the study for?
This trial is for adults over 18 who've had a bone marrow transplant at least a year ago, can consent, and have certain blood count levels. It's not for those with active hepatitis B or C, cancer relapse post-transplant, severe graft-versus-host disease, uncontrolled psychiatric disorders or other serious health conditions.Check my eligibility
What is being tested?
The study tests two groups: one taking Dasatinib and Quercetin supplements after stem cell transplant; the other group only observes standard care without these supplements. The goal is to see if these interventions improve health outcomes.See study design
What are the potential side effects?
Potential side effects of Dasatinib may include immune system effects, bleeding issues, fluid retention and heart problems. Quercetin could cause headaches and tingling in arms/legs. Both might interact with various medications.
HTSS Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have been diagnosed with a condition that requires a stem cell transplant.
Select...
I had a stem cell transplant with chemo or radiation preparation.
Select...
I am 18 years old or older.
HTSS Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 180 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 180 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Frailty
HTSS Trial Design
2Treatment groups
Experimental Treatment
Group I: Group 2: Dasatinib & QuercetinExperimental Treatment2 Interventions
Interventional: The drugs dasatinib and quercetin will be used in this arm
Group II: Group 1: ObservationalExperimental Treatment1 Intervention
Standard of Care - Observation Only
Find a Location
Who is running the clinical trial?
Mayo ClinicLead Sponsor
3,208 Previous Clinical Trials
3,767,040 Total Patients Enrolled
Nathan K LeBrasseur, MS, PhDPrincipal InvestigatorMayo Clinic
Mrinal S Patnaik, M.B.B.SPrincipal InvestigatorMayo Clinic
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My lupus is not under control.I am currently experiencing worsening symptoms of acute graft-versus-host disease.I have worsening overlap graft-versus-host disease.I am taking medication to prevent blood clots.I am a stem cell transplant survivor taking TKI medication for cancer or GVHD.I am currently taking medication for stomach acid.I survived more than a year after my stem cell transplant.I am currently taking quinolone antibiotics.I have been diagnosed with a condition that requires a stem cell transplant.My cancer has returned after a bone marrow transplant.I am unable to understand and give consent for treatment.I am a stem cell transplant survivor with a confirmed drug addiction.I had a stem cell transplant with chemo or radiation preparation.I am a survivor of a stem cell transplant with ongoing heart disease or heart failure.I have fluid buildup that isn't being managed by treatment.I have a new cancer diagnosis, not including non-melanoma skin cancers.I have a fungal or viral infection that isn't getting better with treatment.I am not on medications that strongly affect certain liver enzymes.My family has a history of progeroid syndromes.I have ongoing and worsening chronic GVHD.I am on blood thinners for treatment.I am an HSCT survivor and I have HIV.I am a stem cell transplant survivor with active hepatitis B or C.I am 18 years old or older.My liver function tests are not more than twice the normal limit, unless it's due to Gilbert's syndrome.I cannot take medications by mouth.I have had a stem cell transplant and am on maintenance chemotherapy.
Research Study Groups:
This trial has the following groups:- Group 1: Group 1: Observational
- Group 2: Group 2: Dasatinib & Quercetin
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any openings remaining for prospective participants in this research endeavor?
"Per the details provided on clinicaltrials.gov, this medical trial is seeking participants and was most recently updated on July 18th 2022 after being initially posted February 19th 2016."
Answered by AI
Are there any precedents of Dasatinib being used in the past for medical research?
"Currently, Dasatinib is under exploration in 68 active clinical studies with 9 of those trials having reached Phase 3. A large number of trial locations (4262) are available for this medication - the majority being concentrated around New york City."
Answered by AI
How many individuals are being recruited for participation in this research?
"Affirmative. The clinical trial is still recruiting, as indicated by the information on clinicaltrials.gov. This study was initially posted on February 19th 2016 and last updated July 18th 2022; it seeks to enrol 10 participants from one site."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger